{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:03:44Z","timestamp":1780049024159,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100015086","name":"AOP Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13318-026-00994-3","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:27:30Z","timestamp":1775060850000},"page":"305-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Landiolol and Its Metabolite M1 During Renal Replacement Therapy in Septic Shock Patients: A Sub-Study of the Landi-SEP Trial"],"prefix":"10.1007","volume":"51","author":[{"given":"Sebastian","family":"Rehberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Borgstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"\u010cern\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9832-6526","authenticated-orcid":false,"given":"Jan","family":"Sus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Klade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Krejcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairi","family":"Kirchbaumer-Baroian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Krumpl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Du\u0161ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the LANDI-SEP Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"994_CR1","unstructured":"DrugBank Online. Landiolol (DB12212) [Internet]. DrugBank Online; [cited 2026 March 24]. Available from: https:\/\/go.drugbank.com\/drugs\/DB12212"},{"key":"994_CR2","unstructured":"DrugBank Online. Landiolol hydrochloride (DBSALT002156) [Internet]. DrugBank Online; [cited 2026 March 24]. Available from: https:\/\/go.drugbank.com\/salts\/DBSALT002156"},{"issue":"1","key":"994_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40360-020-00462-x","volume":"21","author":"G Krumpl","year":"2020","unstructured":"Krumpl G, Ulc I, Trebs M, Kadlecova P, Hodisch J. Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults. BMC Pharmacol Toxicol. 2020;21(1):82.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"994_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/FJC.0000000000000554","volume":"71","author":"G Krumpl","year":"2018","unstructured":"Krumpl G, Ulc I, Trebs M, Kadlecova P, Hodisch J, Maurer G, et al. Pharmacokinetics and pharmacodynamics of low-, intermediate-, and high-dose landiolol and esmolol during long-term infusion in healthy Whites. J Cardiovasc Pharmacol. 2018;71(3):137\u201346.","journal-title":"J Cardiovasc Pharmacol"},{"key":"994_CR5","unstructured":"U.S. Food and Drug Administration (FDA). RAPIBLYK (landiolol hydrochloride) for injection: Prescribing Information (Product Label). 2024."},{"key":"994_CR6","unstructured":"College ter Beoordeling van Geneesmiddelen (CBG-MEB; Medicines Evaluation Board, The Netherlands). Public Assessment Report (PAR): Scientific discussion\u2014Rapibloc 300 mg and 600 mg powder for solution for infusion; Rapibloc 20 mg\/2 mL concentrate for solution for injection (landiolol hydrochloride). NL\/H\/3368\/001-003\/DC. Date: 16 Jul 2020."},{"issue":"Suppl A","key":"994_CR7","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1093\/eurheartj\/sux037","volume":"20","author":"H Domanovits","year":"2018","unstructured":"Domanovits H, Wolzt M, Stix G. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl. 2018;20(Suppl A):A1\u20133.","journal-title":"Eur Heart J Suppl"},{"issue":"9","key":"994_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40265-013-0077-4","volume":"73","author":"GL Plosker","year":"2013","unstructured":"Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013;73(9):959\u201377.","journal-title":"Drugs"},{"issue":"8","key":"994_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1253\/circrep.CR-20-0017","volume":"2","author":"T Shiga","year":"2020","unstructured":"Shiga T, Ikeda T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R, et al. Efficacy and safety of landiolol in patients with ventricular tachyarrhythmias with or without renal impairment - subanalysis of the J-Land II study. Circ Rep. 2020;2(8):440\u20135.","journal-title":"Circ Rep"},{"issue":"4","key":"994_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00228-016-2176-0","volume":"73","author":"G Krumpl","year":"2017","unstructured":"Krumpl G, Ulc I, Trebs M, Kadlecova P, Hodisch J. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. Eur J Clin Pharmacol. 2017;73(4):417\u201328.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"994_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2133\/dmpk.20.337","volume":"20","author":"M Murakami","year":"2005","unstructured":"Murakami M, Furuie H, Matsuguma K, Wanibuchi A, Kikawa S, Irie S. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metab Pharmacokinet. 2005;20(5):337\u201344.","journal-title":"Drug Metab Pharmacokinet"},{"key":"994_CR12","unstructured":"Rapibloc 300 Mg Powder for Solution for Infusion - SmPC [Internet]. 2022. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/13830\/smpc#gref. Accessed 7 Mar 2023]"},{"issue":"1","key":"994_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.116.232884","volume":"359","author":"S Nasrollahi-Shirazi","year":"2016","unstructured":"Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C. Comparison of the beta-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions. J Pharmacol Exp Ther. 2016;359(1):73\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"994_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020134","author":"S Schnaubelt","year":"2023","unstructured":"Schnaubelt S, Eibensteiner F, Oppenauer J, Tihanyi D, Neymayer M, Brock R, et al. Hemodynamic and rhythmologic effects of push-dose landiolol in critical care-a retrospective cross-sectional study. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16020134.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"994_CR15","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00134-024-07587-1","volume":"50","author":"S Rehberg","year":"2024","unstructured":"Rehberg S, Frank S, Cerny V, Cihlar R, Borgstedt R, Biancofiore G, et al. Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. 2024;50(10):1622\u201334.","journal-title":"Intensive Care Med"},{"issue":"1","key":"994_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s13063-018-3024-6","volume":"19","author":"M Unger","year":"2018","unstructured":"Unger M, Morelli A, Singer M, Radermacher P, Rehberg S, Trimmel H, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials. 2018;19(1):637.","journal-title":"Trials"},{"issue":"8","key":"994_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"3","key":"994_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","volume":"45","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486\u2013552.","journal-title":"Crit Care Med"},{"key":"994_CR19","unstructured":"European Medicines Agency (EMA). Guideline on bioanalytical method validation. EMEA\/CHMP\/EWP\/192217\/2009 Rev.1 Corr.2 (last updated 3 Jun 2015)."},{"key":"994_CR20","unstructured":"European Medicines Agency (EMA). Reflection paper on laboratories that perform the analysis or evaluation of clinical trial samples. EMA\/INS\/GCP\/532137\/2010 (28 Feb 2012)."},{"key":"994_CR21","unstructured":"Republic of Austria. Gute Laborpraxis 2006 (BGBl. II No. 450\/2006), referring to Annex I of Directive 2004\/10\/EC (OECD GLP principles)."},{"issue":"18","key":"994_CR22","doi-asserted-by":"publisher","first-page":"8959","DOI":"10.1021\/ac5018265","volume":"86","author":"H Gu","year":"2014","unstructured":"Gu H, Liu G, Wang J, Aubry AF, Arnold ME. Selecting the correct weighting factors for linear and quadratic calibration curves with least-squares regression algorithm in bioanalytical LC-MS\/MS assays and impacts of using incorrect weighting factors on curve stability, data quality, and assay performance. Anal Chem. 2014;86(18):8959\u201366.","journal-title":"Anal Chem"},{"issue":"4","key":"994_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/clpt.1986.207","volume":"40","author":"CE Halstenson","year":"1986","unstructured":"Halstenson CE, Opsahl JA, Pence TV, Luke DR, Sirgo MA, Plachetka JR, et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther. 1986;40(4):462\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"994_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF00558446","volume":"17","author":"A Roux","year":"1980","unstructured":"Roux A, Aubert P, Guedon J, Flouvat B. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol. 1980;17(5):339\u201348.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"994_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2125.1980.tb01065.x","volume":"9","author":"B Flouvat","year":"1980","unstructured":"Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A, et al. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. Br J Clin Pharmacol. 1980;9(4):379\u201385.","journal-title":"Br J Clin Pharmacol"},{"key":"994_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112362","author":"H Hafsa","year":"2022","unstructured":"Hafsa H, Zamir A, Rasool MF, Imran I, Saeed H, Ahmad T, et al. Development and evaluation of a physiologically based pharmacokinetic model of labetalol in healthy and diseased populations. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14112362.","journal-title":"Pharmaceutics"},{"issue":"2","key":"994_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00003088-198409020-00003","volume":"9","author":"JJ McNeil","year":"1984","unstructured":"McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. Clin Pharmacokinet. 1984;9(2):157\u201367.","journal-title":"Clin Pharmacokinet"},{"key":"994_CR28","unstructured":"DrugBank Online. Labetalol (DB00598) [Internet]. DrugBank Online; [cited 2026 March 24]. Available from: https:\/\/go.drugbank.com\/drugs\/DB00598 ["},{"issue":"2","key":"994_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1067\/mcp.2000.108733","volume":"68","author":"H Atarashi","year":"2000","unstructured":"Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68(2):143\u201350.","journal-title":"Clin Pharmacol Ther"},{"key":"994_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3918\/jsicm.17.77","volume":"17","author":"T Kono","year":"2010","unstructured":"Kono T, Yanagiya N, Nishimura K. Successful treatment of supraventricular tachyarrhythmias with landiolol during hemodialysis in a patient after receiving cardiac surgery. J Jpn Soc Intensive Care Med. 2010;17:77\u20138.","journal-title":"J Jpn Soc Intensive Care Med"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-00994-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:28:53Z","timestamp":1780046933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-00994-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-00994-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jan Sus, Martin Unger, Christoph Klade, Kurt Krejcy, Nairi Kirchbaumer-Baroian, and Olivier Bouvet are employees of AOP Orphan Pharmaceuticals GmbH. G\u00fcnther Krumpl is a Board Director of AOP Health International Management AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are openly available in EU Clinical Trials Register at\u00a0\n                      \n                      , EudraCT Number: 2017-002138-22.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The trial protocol was approved by the responsible ethics committees: in Germany (reference no.FF 06\/17n; approval date 01 April 2020) and in the Czech Republic (reference no. 202002 I49M; approval date 6February 2020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all patients or their legal representativesprior to any interventions. Additionally, specifi c informed consent was required for participation in the sub-study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The manuscript contains only anonymized, aggregated data and does not include anypersonally identifi able participant information; therefore, consent for publication is not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"As this PK sub-study included only patients who received landiolol, the randomization code isnot applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}